Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€140.70
27.11.21
€160.00
27.11.22
21.35%
28.11.22

Could be worthwhile Investment >10% per year
Significant cyclical dependencies
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€533.60
09.11.21
€600.00
09.11.22
38.91%
10.11.22

Could be worthwhile Investment >10% per year
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€533.60
09.11.21
€600.00
09.11.22
38.91%
10.11.22

Could be worthwhile Investment >10% per year
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€533.60
09.11.21
€600.00
09.11.22
38.91%
10.11.22

Could be worthwhile Investment >10% per year
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€338.70
07.10.22
€350.00
07.10.23
7.12%
29.10.22

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€59.87
15.05.22
€68.00
15.05.23
32.12%
28.10.22

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€59.87
15.05.22
€68.00
15.05.23
32.12%
28.10.22

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€59.87
15.05.22
€68.00
15.05.23
32.12%
28.10.22

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
buy
Merck & Co. Inc.

Start price
Target price
Perf. (%)
€69.88
11.10.21
€76.00
11.10.22
26.36%
22.07.22

buy
Merck & Co. Inc.

Start price
Target price
Perf. (%)
€69.88
11.10.21
€76.00
11.10.22
26.36%
22.07.22

Biogen Inc.

Start price
Target price
Perf. (%)
€282.65
28.06.21
€240.00
28.06.22
-31.92%
29.06.22

Biogen Inc.

Start price
Target price
Perf. (%)
€282.65
28.06.21
€240.00
28.06.22
-31.92%
29.06.22

Biogen Inc.

Start price
Target price
Perf. (%)
€282.65
28.06.21
€240.00
28.06.22
-31.92%
29.06.22

buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€158.36
17.06.21
€165.00
17.06.22
59.60%
18.06.22

Could be worthwhile Investment >10% per year
buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€158.36
17.06.21
€165.00
17.06.22
59.60%
18.06.22

Could be worthwhile Investment >10% per year
buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€158.36
17.06.21
€165.00
17.06.22
59.60%
18.06.22

Could be worthwhile Investment >10% per year
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€32.84
17.05.21
€37.00
17.05.22
47.77%
18.05.22

buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€32.84
17.05.21
€37.00
17.05.22
47.77%
18.05.22

buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€32.70
09.05.21
€35.00
09.05.22
40.49%
10.05.22

buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€32.70
09.05.21
€35.00
09.05.22
40.49%
10.05.22

buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€29.88
21.03.21
€35.00
21.03.22
64.07%
22.03.22

buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€29.88
21.03.21
€35.00
21.03.22
64.07%
22.03.22

buy
AbbVie Inc.

Start price
Target price
Perf. (%)
€115.90
16.12.21
€120.00
16.03.22
23.37%
16.03.22

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€463.95
25.01.21
€500.00
25.01.22
15.42%
26.01.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€463.95
25.01.21
€500.00
25.01.22
15.42%
26.01.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group